HDR Brachytherapy, EBRT and STAD for the Treatment of Prostate Cancer (BEACON)
A Phase I/II Study of Salvage High-dose-rate Brachytherapy, ExternAl Beam COmbined and Short-term Hormonal Therapy for the Treatment of Node-positive Locally Recurrent Prostate Cancer After Prior Definitive Radiotherapy
Sponsor: Loyola University
Terminated
The study was stopped for feasibility
This PHASE1/PHASE2 trial investigates Prostate Cancer - Recurrent and is currently terminated or withdrawn. Loyola University leads this study, which shows 8 recorded versions since 2017 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Feb 2026 — Present [monthly]
Terminated PHASE1/PHASE2
Status: Unknown → Terminated
-
Sep 2024 — Feb 2026 [monthly]
Unknown PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1/PHASE2
Status: Recruiting → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Jul 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 3 earlier versions
-
Feb 2020 — Jul 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2019 — Feb 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Jul 2018 — Mar 2019 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Dec 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Loyola University
For direct contact, visit the study record on ClinicalTrials.gov .